Trending...
- Sober.Buzz the Sober Token : Ticker $BUZZ
- DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
- Meditech International Inc. and Los Angeles Rams Continue Strategic Partnership to Enhance Athlete Performance and Recovery
PHILADELPHIA, Dec. 7, 2023 /PRNewswire/ -- Berger Montague PC is currently investigating potential violations of the federal securities laws on behalf of shareholders of Eagle Pharmaceuticals, Inc. ("Eagle") (NASDAQ: EGRX).
Eagle is a pharmaceutical company focused on developing treatments for diseases of the central nervous system or metabolic critical care, as well as oncology.
On November 9, 2023, Eagle disclosed that it would not be able to timely file its quarterly report for the second quarter of 2023 because it required additional time to complete its review of potential adjustments relating to the reporting of sales of PEMFEXY.
On this news, the price of Eagle shares fell $4.16 per share, or 30%, to close at $9.54 per share on November 9, 2023.
Then, on November 29, 2023, Eagle disclosed in a filing with the U.S. Securities and Exchange Commission that Eagle's President and Chief Executive Officer, Scott Tarriff, was resigning and that the board of directors accepted the resignation "[a]fter consideration of various alternatives, including termination with or without cause."
More on The PennZone
On this news, Eagle's share price fell $2.55, or 31%, to close at $5.68 per share on November 29, 2023.
If you are an Eagle investor and would like to learn more about our investigation, please contact Berger Montague: James Maro at [email protected] or (267) 637-3176, or Andrew Abramowitz at [email protected] or (215) 875-3015 or CLICK HERE.
Whistleblowers: Anyone with non-public information regarding Eagle is encouraged to confidentially assist Berger Montague's investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.
More on The PennZone
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
Contacts:
James Maro, Senior Counsel
Berger Montague
(267) 637-3176
[email protected]
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
SOURCE Berger Montague
Eagle is a pharmaceutical company focused on developing treatments for diseases of the central nervous system or metabolic critical care, as well as oncology.
On November 9, 2023, Eagle disclosed that it would not be able to timely file its quarterly report for the second quarter of 2023 because it required additional time to complete its review of potential adjustments relating to the reporting of sales of PEMFEXY.
On this news, the price of Eagle shares fell $4.16 per share, or 30%, to close at $9.54 per share on November 9, 2023.
Then, on November 29, 2023, Eagle disclosed in a filing with the U.S. Securities and Exchange Commission that Eagle's President and Chief Executive Officer, Scott Tarriff, was resigning and that the board of directors accepted the resignation "[a]fter consideration of various alternatives, including termination with or without cause."
More on The PennZone
- Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
- Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
On this news, Eagle's share price fell $2.55, or 31%, to close at $5.68 per share on November 29, 2023.
If you are an Eagle investor and would like to learn more about our investigation, please contact Berger Montague: James Maro at [email protected] or (267) 637-3176, or Andrew Abramowitz at [email protected] or (215) 875-3015 or CLICK HERE.
Whistleblowers: Anyone with non-public information regarding Eagle is encouraged to confidentially assist Berger Montague's investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.
More on The PennZone
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
Contacts:
James Maro, Senior Counsel
Berger Montague
(267) 637-3176
[email protected]
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
SOURCE Berger Montague
Filed Under: Business
0 Comments
Latest on The PennZone
- Hubei Heavy Equipment Makes a Striking Appearance at CIMT and Competes with International Brands
- 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
- NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
- Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
- Chewy Chums™ Launches NeverBite™ on Kickstarter
- DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
- Fangzhou Launches Otsuka's Third-Generation Leukemia Drug Ponatinib on its Platform
- Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
- Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
- Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
- $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
- Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
- xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
- Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
- New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions
- Immorta Bio to Present SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting
- "Stop scrolling and start watching" - Beloved film recommendation site Criticker gets a major makeover
- Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
- Events by Dubsdread Expands Services to The Venue at Lake Lily
- London Gala Emphasizes Trade, FDI and Ongoing Cooperation